# Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC

Source: https://onco.cc/trials/nct04875585/  
OnCo record `nct04875585` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of pembrolizumab and lenvatinib in lung cancer, run by Medical University Innsbruck, now recruiting.

## Summary

Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC is a phase 2, interventional study registered as NCT04875585 by Medical University Innsbruck, with a registry enrolment figure of 33 participants, started 2021-05-12 and due to reach its primary completion in 2023-12. Interventions recorded: neoadjuvant therapy with Pembrolizumab/Lenvatinib; Surgery; Adjuvant Treatment Phase. Conditions listed: Non Small Cell Lung Cancer. Primary outcome: Major pathological response after neoadjuvant immunotherapy in combination with angiogenesis inhibition. Lung eligibility wording from the registry: "Histologically confirmed primary diagnosis of resectable NSCLC, stages IA3-IIIA (max". Sites: Austria. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: INNWOP1
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT04875585
- Phase: 2
- Setting: Phase II Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib and Adjuvant Pembrolizumab in Patients With Surgically Resectable Non-Small- Cell Lung Cancer (NSCLC)
- Sponsor: Medical University Innsbruck
- Enrolled: 33

## Sources

- ClinicalTrials.gov NCT04875585: https://clinicaltrials.gov/study/NCT04875585

## Connected records

- cancers: [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Lenvatinib](https://onco.cc/drugs/lenvatinib/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04875585.json